Introduction {#Sec1}
============

The role of microbiota is being revisited due to its emerging role in pathologies that were previously considered non-microbial^[@CR1],[@CR2]^. For instance, bacteriophages have been recently found to be associated with the development of specific human diseases, such as Parkinson's disease and type 1 diabetes^[@CR3]--[@CR5]^. Moreover, particular attention has been paid to pathogen-associated molecular patterns (PAMPs), mainly represented by components of microbial biofilms, including those of the gut microbiota^[@CR6]^. One example is bacterial extracellular DNA (eDNA). Bacteria produce large amounts of eDNA that plays a multifunctional role in microbial biofilms, as a structural component, a nutrient during starvation, a promoter of colony spreading, and a pool for horizontal gene transfer^[@CR7]--[@CR9]^. eDNA is also known to affect bacterial protein modification in biofilm matrix, as exemplified by its role in the conversion of bacterial water-soluble proteins into extracellular insoluble β-sheet-rich amyloid structures, such as self-propagation and resistance to proteases and heat^[@CR10]--[@CR12]^. Heat resistance is a hallmark of prion proteins, although its biological significance is not clear. Notably, heat resistance is not an exclusive property of prion proteins or proteins implicated in heat-shock events, but can also be due to the occurrence of specific mutations in mammalian proteins that are normally not thermo-resistant, which makes this phenomenon even more puzzling^[@CR13],[@CR14]^.

The properties of bacterial eDNA have been poorly investigated, except for its actions in the context of microbial biofilms. On the other hand, the chances that the eDNA secreted from microbial communities interacts with human proteins are relatively high. For example, eDNA released during biofilm spreading or lytic bacteriophage infection can enter the systemic circulation by different pathways, also facilitated by the altered intestinal permeability that accompanies the increased absorption of PAMPs^[@CR15]--[@CR17]^. Increasing evidence shows that impaired gut barrier dysfunction is an important determinant for the increase in circulating bacterial DNA that is associated with different diseases. Indeed, increased levels of both bacterial eDNA and human cfDNA characterize various pathological human conditions including cancer, stroke, traumas, autoimmune disorders, and sepsis^[@CR18]--[@CR21]^.

Another way by which PAMPs can enter biological fluids is their release from bacteria localized within the "internal environment" such as brain or placenta^[@CR22]--[@CR25]^. Moreover, DNA can be released into eukaryotic cells from obligate and facultative intracellular bacteria^[@CR26],[@CR27]^.

Thus, despite the fact that interactions between bacterial eDNA and humans are very likely to occur, the effects of bacterial eDNA within body fluids are poorly studied, except for the CpG motif-induced activation of proinflammatory reactions through Toll-like receptor 9^[@CR28]^. In this study, we evaluated a novel effect of bacterial eDNA on blood plasma proteins, which resulted in the alteration of the heat resistance of these proteins.

Results {#Sec2}
=======

eDNA-induced alteration of protein heat resistance in the plasma of healthy controls {#Sec3}
------------------------------------------------------------------------------------

We first studied the effects of DNA on the thermal behavior of proteins from the plasma of healthy individuals. Most proteins were aggregated after boiling, and the supernatant contained heat-resistant fractions of over 100 proteins. The identified heat-resistant proteins had a molecular weight ranging between 8 kDa and 263 kDa. Treatment with bacterial and human buffy coat DNA altered the composition of the heat-resistant protein fraction. We first verified which plasma proteins, among those that were heat-resistant before treatment with DNA, exhibited an increased level following DNA exposure in at least one healthy control (Table [1](#Tab1){ref-type="table"}).Table 1Heat-resistant proteins of healthy controls whose amount increased following treatment with different DNAs.NAccession No UniProtUniprot AccessionProtein name**eDNA of** ***P. aeruginosa***1P02768ALBU_HUMANSerum albumin2P02751FINC_HUMANFibronectin3B4E1Z4B4E1Z4_HUMAcDNA FLJ55673, highly similar to Complement factor B4P02774VTDB_HUMANVitamin D-binding protein5P01859IGHG2_HUMANImmunoglobulin heavy constant gamma 26P00747PLMN_HUMANPlasminogen7Q14624ITIH4_HUMANInter-alpha-trypsin inhibitor heavy chain H48Q5T987ITIH2_HUMANInter-alpha-trypsin inhibitor heavy chain H29P04114APOB_HUMANApolipoprotein B-10010O14791APOL1_HUMANApolipoprotein L111P19652A1AG2_HUMANAlpha-1-acid glycoprotein 212P20851C4BPB_HUMANC4b-binding protein beta chain13P01857IGHG1_HUMANImmunoglobulin heavy constant gamma 1**eDNA of S.aureus**1P02652APOA2_HUMANApolipoprotein A-II**eDNA of S.mitis**1P02652APOA2_HUMANApolipoprotein A-II**eDNA of E.coli**1P19652A1AG2_HUMANAlpha-1-acid glycoprotein 22P04114APOB_HUMANApolipoprotein B-1003P20851C4BPB_HUMANC4b-binding protein beta chain^\*^Significant fold change in the level of heat-resistant proteins between normal plasma and plasma treated with eDNA for the proteins with spectrum counts \<200 and over 30% increase for the proteins with spectrum counts \>200\*.

We next measured the increase in heat-resistant protein fractions following the treatment of plasma with bacterial eDNA. The highest increase in heat-resistant fractions of different unrelated proteins was registered after incubation with the eDNA of *Pseudomonas aeruginosa*. Interestingly, eDNA from different bacteria produced distinct effects. Indeed, the exposure to eDNA from the gram-positive bacteria, *Staphylococcus aureus* and *Streptococcus mitis* resulted in a selective increase in heat-resistant APOA2, which was not observed after treatment with eDNA from gram-negative bacteria. Under the same conditions, *E. coli* eDNA increased the heat-resistant fractions of A1AG2, APOB, and C4BP; however, the latter heat-resistant fractions were also increased after exposure to *P. aeruginosa* eDNA.

Intriguingly, specific proteins that did not exhibit a heat-resistant fraction in untreated plasma samples became heat-resistant following eDNA exposure. Table [2](#Tab2){ref-type="table"} lists the proteins that displayed such a behavior in at least one of the plasma samples.Table 2Proteins that became heat-resistant following eDNA treatment but had no heat resistant fractions before.NAccession No UniProtUniprot AccessionProtein name**eDNA of P.aeruginosa**1P69905HBA_HUMANHemoglobin subunit alpha2Q03591FHR1_HUMANComplement factor H-related protein 13P01031CO5_HUMANComplement C54A0M8Q6IGLC7_HUMANImmunoglobulin lambda constant 75O43866CD5L_HUMANCD5 antigen-like6P49908SEPP1_HUMANSelenoprotein P7P0DOY3IGLC3_HUMANImmunoglobulin lambda constant 38P63241IF5A1_HUMANEukaryotic translation initiation factor 5A-19P04264K2C1_HUMANCluster of Keratin, type II cytoskeletal 110P35527K1C9_HUMANKeratin, type I cytoskeletal 911P13645K1C10_HUMANKeratin, type I cytoskeletal 1012A0A075B6S5KV127_HUMANImmunoglobulin kappa variable 1--27**eDNA of** E.coli1Q9P2D1CHD7_HUMANChromodomain-helicase-DNA-binding protein 72Q9UGM5FETUB_HUMANFetuin-B3P01857IGHG1_HUMANImmunoglobulin heavy constant gamma 14P01861IGHG4_HUMANImmunoglobulin heavy constant gamma 45P01718IGLV3--27Immunoglobulin lambda variable 3--276P20151KLK2Kallikrein-27Q8TBK2SETD6_HUMANN-lysine methyltransferase SETD68P18583SON_HUMANProtein SON9O95980RECK_HUMANReversion-inducing cysteine-rich protein with Kazal motifs10P02787TRFE_HUMANSerotransferrin11P49908SEPP1_HUMANSelenoprotein P12P0DOY3IGLC3_HUMANImmunoglobulin lambda constant 313P63241IF5A1_HUMANEukaryotic translation initiation factor 5A-114P13645K1C10_HUMANKeratin, type I cytoskeletal 10**Human DNA**1P04264K2C1_HUMANCluster of Keratin, type II cytoskeletal 12P35527K1C9_HUMANKeratin, type I cytoskeletal 93P13645K1C10_HUMANKeratin, type I cytoskeletal 10

These findings clearly demonstrated that human DNA and eDNA from different bacteria had a distinct influence on the generation of heat-resistant protein fractions. Notably, we did not detect any proteins with decreased heat-resistance following the exposure to eDNA.

To further analyze the correlation between DNA exposure and acquisition of heat resistance, we constructed a heat map summarizing the impact of different DNAs on the thermal behavior of proteins (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Heatmap of proteins of normal plasma samples that altered their heat resistant characteristics following the treatment with different DNA. The heat map represents the relative effects of DNA from different sources on the proportion of heat-resistant proteins in normal plasma. The colour intensity is a function of protein spectrum counts, with bright yellow and black indicating maximal counts and lack of detection, respectively.

Plasma exposure to the eDNA of *P. aeruginosa* resulted in the formation of 12 heat-resistant proteins. Notably, only a subset of these proteins, namely K1C10, SEPP1, IGLC3, and IF5A1, also acquired heat resistance after treatment with the DNA of another gram-negative bacteria, *E. coli*. The latter, in turn, changed the heat resistance profile of distinct proteins in the same plasma samples.

Whereas bacterial eDNA induced heat resistance of a broad spectrum of unrelated proteins, plasma exposure to human DNA only affected the thermal behavior of a specific group of proteins, i.e., cytoskeletal keratins.

Since prion domains may be responsible for protein heat resistance, we next employed the prion-prediction PLAAC algorithm to verify the presence of PrDs in proteins exhibiting changes in thermal behavior following DNA treatment.

PrDs were only found in CHD7 and K1C10, which became heat-resistant following the exposure to *E. coli* eDNA, and keratins (K2C1, K1C9, K1C10), which acquired heat resistance upon treatment with both *P. aeruginosa* eDNA and human DNA (Table [3](#Tab3){ref-type="table"}). Notably, the above keratins were the only proteins undergoing thermal behavior alterations following exposure to human DNA.Table 3Log-likelihood ratio (LLR) score for PrD predictions in plasma proteins that became heat-resistant following DNA treatment.ProteinLLR ScoreCHD729.081K2C121.301K1C922.663K1C1021.453

We next analyzed the association between DNA-induced changes in protein thermal behavior and human diseases. Surprisingly, the majority of these proteins were previously found to be associated with cancer progression, and some of them are used as a tumor markers (Table [4](#Tab4){ref-type="table"}).Table 4Association between proteins exhibiting DNA-induced changes in thermal behavior and human diseasesDiseaseProteinsReferencesPancreatic cancer• Serotransferrin• Complement factor H-related protein• Plasma protease C1 inhibitor• Fibronectin• Immunoglobulin lambda constant 7• C4b-binding protein alpha chain• Selenoprotein P^[@CR45],[@CR46],[@CR63]--[@CR71]^Colorectal cancerAPOBSETD6Reversion-inducing cysteine-rich protein with Kazal motifs (RECK)^[@CR72]--[@CR74]^Ovarian cancerHemoglobin-αEukaryotic translation initiation factor 5A-1FibronectinInter-α-trypsin inhibitor heavy chain H4 fragment^[@CR75]--[@CR78]^Breast cancerInter-α-trypsin inhibitor heavy chain H4 fragment^[@CR78]^Lung CancerITIH4Complement Factor HPlasma protease C1 inhibitorImmunoglobulin lambda constant 7CD5L^[@CR51],[@CR79]--[@CR82]^hairy cell leukemia.Immunoglobulin kappa variable 1--27^[@CR83]^melanomaCD5 antigen-likeKeratin, type I cytoskeletal 9^[@CR84],[@CR85]^Prostatic cancerSelenoprotein Pkallikrein 2apolipoprotein A-II^[@CR47],[@CR86]--[@CR89]^Bladder cancerSETD6Complement factor H-related protein^[@CR90],[@CR91]^ThalassemiaHBA^[@CR92]^

Intriguingly, some of these cancer-related proteins are also known to be associated with other multifactorial diseases. For example, ITIH4 is associated with schizophrenia and CHD7 is implicated in autism^[@CR29]--[@CR31]^.

Comparison of heat-resistant proteome profile in normal, DNA-treated, and pancreatic cancer plasma {#Sec4}
--------------------------------------------------------------------------------------------------

We then examined the changes in protein thermal behavior induced by DNA in normal plasma and compared the resulting pattern with the heat-resistant proteome of patients with pancreatic cancer (Table [5](#Tab5){ref-type="table"}).Table 5Characteristics of subjects and plasma samples.ProbeGenderAgeTumour StageTumour siteTumour typeControl 1F64NANANAControl 2F55NANANAControl 3M57NANANAControl 4M62NANANAControl 5M58NANANAControl 6F61NANANAControl 7F66NANANAControl 8M66NANANAControl 9M63NANANAControl 10F60NANANAPancreatic cancer 1F63T3N1M1HeadAdenocarcinomaPancreatic cancer 2M57T3N1M1HeadAdenocarcinomaPancreatic cancer 3F56T3N1M1HeadAdenocarcinomaPancreatic cancer 4F69T3N1M1HeadAdenocarcinomaPancreatic cancer 5M61T3N1M1HeadAdenocarcinomaPancreatic cancer 6M52T3N1M1HeadAdenocarcinomaPancreatic cancer 7F59T2N1M1HeadAdenocarcinomaPancreatic cancer 8M72T3N1M1HeadAdenocarcinomaPancreatic cancer 9F64T2N1M1HeadAdenocarcinomaPancreatic cancer 10F71T3N1M1HeadAdenocarcinoma

After boiling, the plasma samples of patients with pancreatic cancer were characterized for the presence of heat-resistant proteins. The majority of these proteins were the same that became heat-resistant in normal plasma exposed to DNA treatment. This suggested that DNA exposure was responsible for cancer-related alterations in the thermal behavior of specific proteins.

To further explore the relationship between the heat-resistant proteome of patients with pancreatic cancer and the proteome changes induced by DNA in the plasma of healthy individuals, we analyzed the scaled spectral counts of the identified heat-resistant proteins in both groups by principal component analysis (PCA) (Fig. [2A](#Fig2){ref-type="fig"}).Figure 2Principal component analysis (PCA) and heat map of proteome data. (**A**) Principal component analysis reflecting the similarities between the heat-resistant proteome of pancreatic cancer plasma and that of plasma from healthy controls following treatment with different DNAs (eby LC/MS). The strongest similarity trend between the plasma of cancer patients and that of healthy subjects after exposure to the eDNA of *P. aeruginosa* are shown. (**B**) Heat map showing the mean spectrum counts of heat-resistant proteins in normal plasma samples following DNA treatment, and in the plasma of patients with pancreatic cancer. Black colour and yellow colours represent low and high spectral counts, respectively.

The PCA projection demonstrated that the exposure to bacterial DNA (especially the eDNA of *P. aeruginosa*), induced, in the proteome of normal plasma, changes in thermal behavior.

A heat map based on the highest spectral counts relative to heat-resistant proteins confirmed that treatment of normal plasma with eDNA of *P. aeruginosa* induced a heat-resistant proteome with a higher degree of similarity to that of plasma from cancer patients, compared to that of untreated plasma (Fig. [2B](#Fig2){ref-type="fig"}).

Discussion {#Sec5}
==========

This study is the first to demonstrate that bacterial eDNA alters the thermal behavior of specific proteins in human plasma, leading to an increase in the heat-resistant fraction, as well as to the acquisition of heat resistance by proteins that did not exhibit such property prior to DNA exposure.

We discovered that bacterial eDNA or human DNA led to the appearance of different heat-resistant proteins, depending on the DNA source.

Furthermore, we identified a differential effect of eDNA from various gram-positive and gram-negative bacteria on the thermal behavior of plasma proteins. In fact, we surprisingly found that eDNA from different bacteria interacted with distinct plasma proteins (Table [1](#Tab1){ref-type="table"}).

Notably, among the 35 identified proteins with increased heat-resistance following DNA exposure, according to literature data and BindUP tool, only 3 have been previously reported to be able to bind nucleic acids, namely, fibronectin, chromodomain-helicase-DNA-binding protein 7, and SON^[@CR32]--[@CR34]^.

Heat resistance was previously described only for complement factor H and fibronectin, whereas the other proteins found to contain heat-resistant fragments in this study were not known to possess this property^[@CR35]--[@CR37]^.

Previous studies have shown that one possible mechanism responsible for the acquisition of heat resistance is the formation of β-structures, which confer increased stability to chemical and physical agents^[@CR38]--[@CR42]^.

Within this framework, we studied the presence of PrDs in proteins that were found to acquire heat resistance upon DNA exposure and predicted the presence of PrDs only in cytoskeletal and microfibrillar keratins I and II, and in chromodomain-helicase-DNA-binding protein 7^[@CR43]^. These proteins exhibited a high likelihood ratio (LLR between 21 to 29), and therefore were highly probable to display a prion-like behavior, since the lowest LLR value reported for a known prion-forming protein of budding yeast is \~21.0^[@CR44]^.

Interestingly, PrD-containing K2C1, K1C9, and K1C10 were the only proteins that were found to acquire heat resistance following treatment with human DNA. In addition, the eDNA from *P. aeruginosa* and *E. coli* induced heat resistance in these PrDs-containing proteins.

The majority of proteins undergoing eDNA-dependent changes in heat resistance identified in the current study did not contain PrDs. This suggested that eDNA caused a PrD-independent induction of heat resistance in these proteins. Therefore, we named proteins undergoing DNA-dependent changes in thermal behavior, in the absence of prion-like structure, "Tetz-proteins".

Next, we analyzed the association between proteins that acquired DNA-induced heat resistance and human pathologies. According to the literature, many of them were related to a variety of diseases, predominantly cancers. Consistently, some of them are known as tumor biomarkers and participate in tumor progression^[@CR45]--[@CR48]^.

Our findings suggested a novel role of bacterial eDNA in disease development, and cancer development in particular, consistent with its reported presence of eDNA in the systemic circulation in association with cancer and other human diseases^[@CR20],[@CR49]^. Indeed, recent studies have shown that patients with non-infectious early-onset cancer display elevated plasma levels of eDNA from bacteria, particularly *Pseudomonas spp*., and *Pannonibacter* spp.^[@CR20]^. Therefore, for the treatment of plasma samples we used a fixed concentration of bacterial or human DNA, 1 µg/mL, which was selected based on previous studies reporting the presence of similar concentrations of circulating cfDNA in patients with cancer^[@CR21],[@CR50]^.

We next studied the presence and composition of heat-resistant proteins in the plasma of patients with pancreatic cancer. This type of cancer was selected because the majority of proteins that became heat-resistant following bacterial eDNA exposure had been found to be associated with this pathology.

The heat-resistant proteome of cancer patients was compared with that of control plasma, before and after the exposure to eDNA. PCA revealed that, after treatment with different DNAs, the proteome from control plasma acquired non-statistically significant changes in heat resistance that made it more similar to that of plasma samples from cancer patients. We believe that studies on larger sample cohorts may yield statistically significant results. CD5L, EIF5A1, FINC, and SEPP1 particularly attracted our attention as, according to the literature, they are associated with tumorigenesis^[@CR46],[@CR51]--[@CR53]^. In the present study, heat-resistant fractions of these proteins were identified in pancreatic cancer plasma, but not in normal plasma, and formed only after eDNA treatment, suggesting a role of this conversion in tumorigenesis.

It is tempting to speculate that DNA, including bacterial eDNA, may function as a virulence factor through the interaction with (and the alteration of) Tetz-proteins, including those associated with tumor growth. Therefore, it is possible that under certain conditions, eDNA elevation triggers alterations in plasma proteins that, in turn, may be relevant for tumorigenesis or other pathologies. We also found an effect of eDNA on proteins implicated in neurodegeneration and psychotic disorders. Experiments aimed at the characterization of the pathogenic role of different types of bacterial eDNA are in progress.

Methods {#Sec6}
=======

Plasma samples {#Sec7}
--------------

Human plasma samples from 10 healthy donors (age: 55--66 years, 50% females) and 10 patients with clinically diagnosed pancreatic ductal adenocarcinoma (age: 52--72 years, 50% females) were obtained from Bioreclamation IVT (NY, USA), Discovery Life Sciences (Los Osos, CA), Human Microbiology Institute (NY, USA). All patients with pancreatic ductal adenocarcinoma had been diagnosed by histological examination and had not undergone surgical treatment, preoperative chemotherapy or radiotherapy. The basic demographic characteristics of the patients are shown in Table [4](#Tab4){ref-type="table"}. All samples were obtained with prior informed consent at all facilities. Plasma samples were stored at −80 °C until use. This study was approved by the ethics committee of the Human Microbiology Institute (114--40) and all experiments were performed in accordance with relevant guidelines and regulations.

Extracellular DNA {#Sec8}
-----------------

DNA was extracted from the extracellular matrix of *P. aeruginosa* ATCC 27853, *E. coli* ATCC 25922, *Staphylococcus aureus* ATCC 29213, *Streptococcus mitis* VT-189. All bacterial strains were subcultured from freezer stocks onto Columbia agar plates (Oxoid Ltd., London, England) and incubated at 37 °C for 48 h. To extract the extracellular DNA, bacterial cells were separated from the matrix by centrifugation at 5000 g for 10 min at 4 °C. The supernatant was aspirated and filtered through a 0.2-μm-pore-size cellulose acetate filter (Millipore Corporation, USA). eDNA was extracted by using a DNeasy kit (Qiagen), according to the manufacturer, or by the phenol-chloroform method^[@CR54]^. Human genomic DNA (0.2 g/L in 10 mM Tris--HCl, 1 mM EDTA, pH 8.0, Cat. No. 11691112001) was purchased from Sigma (Sigma-Aldrich) and consisted of a high molecular weight \>50.000 bp genomic DNA isolated from human blood according to the protocol described by Sambrook^[@CR55]^.

Plasma exposure to eDNA {#Sec9}
-----------------------

DNA was added to plasma samples at the final concentration of 1 µg/mL, incubated at 37 °C for 1 h, and boiled in a water bath at 100 °C for 15 min (by that time all the samples formed clods of coagulated proteins). Samples were cooled at room temperature for 30 min and centrifuged at 5000 g for 10 min at room temperature. The supernatant was aspirated and filtered through a 0.2-μm pore size cellulose acetate filter (Millipore Corporation, USA).

Protein identification by LS-MS {#Sec10}
-------------------------------

The filtered protein-containing supernatant was diluted in a final volume of 100 µL using 100 mM ammonium bicarbonate, pH 8, and quantified using a Nanodrop OneC Spectrophotometer (Thermo Fisher Scientific). Cysteine residues were reduced using 5 mM dithiothreitol at room temperature for 1.5 h and alkylated with 10 mM iodoacetamide at room temperature for 45 min in the dark. Proteins were then digested using modified trypsin (Promega, P/N V5113) at a 1:20 (w/w) enzyme:protein ratio for 16 h at 22 °C. After digestion, peptides were acidified to pH 3 with formic acid and desalted using Pierce Peptide Desalting Spin Columns (P/N 89852), according to the manufacturer's protocol. Eluted, desalted peptides were dried down to completion using a Labconco speedvac concentrator, resuspended in 0.1% formic acid and quantified again using a Nanodrop OneC Spectrophotometer^[@CR56]^. For sample injection and mass analysis, peptides were diluted to a final concentration of 500 ng/µL using 0.1% formic acid in water to provide a total injection amount of 500 ng in a 1 µL of sample loop. Peptides were separated and their mass analyzed using a Dionex UltiMate 3000 RSLCnano ultra-high performance liquid chromatograph (UPLC) coupled to a Thermo Scientific Q Exactive HF hybrid quadrupole-orbitrap mass spectrometer (MS). A 1.5 hr reversed-phase UPLC method was used to separate peptides using a nanoEASE m/z peptide BEH C18 analytical column (Waters, P/N 186008795). The MS method included top 15 data-dependent acquisition for interrogation of peptides by MS/MS using HCD fragmentation. All raw data were searched against the human Uniprot protein database (UP000005640, accessed Apr 22, 2017) using the Andromeda search algorithm within the MaxQuant suite (v 1.6.0.1)^[@CR57],[@CR58]^. The search results were filtered to a 1% FPR and visualized using Scaffold (v4, Proteome Software).

A cut-off of at least 5 spectral counts per probe was applied for protein selection^[@CR59]--[@CR61]^.

The obtained data were used to generate a heatmap. The abundance values were log converted (zero values were replaced with infinitely small number "1") and plotted with R-statistical computing (<https://www.r-project.org/>), using the "levelplot" package. The color key indicates a range between the lowest (black) and the highest (yellow) values.

Principal components analysis was performed using the prcomp function with default parameters (zero values were replaced with 1) of the R software (<https://www.r-project.org/>).

Identification of prion-like domains (PrDs) in proteins {#Sec11}
-------------------------------------------------------

The presence of prion-like domains in the proteins was assessed using the PLAAC prion prediction algorithm, which establishes the prionogenic nature on the basis of the asparagine (Q) and glutamine (N) content, using the hidden Markov model (HMM)^[@CR43],[@CR62]^. The output probabilities for the PrD states in PLAAC were estimated based on the amino acid frequencies in the PrDs of *Saccharomyces cerevisiae*. Here, we used Alpha = 0.0, representing species-independent scanning, to identify the PrDs.
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